B of A Securities Downgrades Medical Properties Trust to Neutral

B of A Securities analyst Joshua Dennerlein downgrades Medical Properties Trust (NYSE:MPW) from Buy to Neutral.

byBenzinga Newsdesk

March 11, 2022

1 minute read

B of A Securities analyst Joshua Dennerlein downgrades Medical Properties Trust (NYSE:MPW) from Buy to Neutral.

QuickLogic Wins Embedded FPGA IP Contract, Valued At $1M

By Benzinga Newsdesk

Today, 4:18 AM

QuickLogic Corporation (NASDAQ:QUIK), a developer of ultra-low power multi-core voice-enabled SoCs, embedded FPGA IP (eFPGA), and Endpoint AI solutions, today announced that it has won a new eFPGA contract worth

QUIK

Scotiabank Upgrades Eastman Chemical to Sector Outperform, Announces $145 Price Target

By Benzinga Newsdesk

Today, 4:18 AM

Scotiabank analyst Ben Isaacson upgrades Eastman Chemical (NYSE:EMN) from Sector Perform to Sector Outperform and announces $145 price target.

EMN

Jefferies Maintains Buy on Scorpio Tankers, Raises Price Target to $68

By Benzinga Newsdesk

Today, 4:18 AM

Jefferies analyst Omar Nokta maintains Scorpio Tankers (NYSE:STNG) with a Buy and raises the price target from $65 to $68.

STNG

GlycoMimetics Completes Enrollment Of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan In Patients With Relapsed /Refractory Acute Myeloid Leukemia

By Benzinga Newsdesk

Today, 4:18 AM

GlycoMimetics, Inc. (NASDAQ:GLYC) today announced completion of enrollment of its pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML. A

GLYC

B of A Securities Downgrades Medical Properties Trust to Neutral

Related Posts

QuickLogic Wins Embedded FPGA IP Contract, Valued At $1M

Scotiabank Upgrades Eastman Chemical to Sector Outperform, Announces $145 Price Target

Jefferies Maintains Buy on Scorpio Tankers, Raises Price Target to $68

GlycoMimetics Completes Enrollment Of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan In Patients With Relapsed /Refractory Acute Myeloid Leukemia